Clinical Trials in Minneapolis

Showing 11041-11060 of 14,456 trials

Comparisons of Nicotine-free Cigarettes, Extra Low Nicotine Cigarettes vs. Medicinal Nicotine

NCT00777569

In this study, smokers will be randomly assigned to one of three conditions for six weeks: 1) nicotine-free cigarettes (0.05mg); 2) extra low nicotine cigarettes (0.3 mg); or 3) medicinal 4 mg nicotine lozenge. The tobacco toxin profiles across these various products will be compared. The effects of these products on biomarkers of exposure and risk factors for disease, compensatory smoking, components of tobacco addiction and short-term smoking cessation will be determined. Predictors of response to these products (e.g., compensatory smoking, compliance with product use, time to lapse) will also be examined. The following primary hypothesis will be tested: 1) Extent of tobacco toxin exposure will be greatest for the extra low nicotine cigarette and least for nicotine lozenge. Other secondary hypotheses include: 2) Compensatory smoking, as calculated by using cotinine, will be greatest for the extra low cigarette compared to the nicotine-free cigarette; 3) Greater positive subjective responses to cigarettes will be observed with extra low nicotine vs. nicotine-free cigarette; 4) Similar withdrawal symptoms and negative affect will be observed with nicotine-free cigarette and nicotine lozenge, and least withdrawal and negative affect with the extra low nicotine cigarette; 6) Least dependence and greatest motivation and self-efficacy to quit will be observed with nicotine lozenge and the greatest dependence and least motivation and self-efficacy to quit with the extra low nicotine cigarette use; 7) Shorter time to lapse will be observed with extra low nicotine vs. nicotine-free cigarettes because of extinction is likely to occur with nicotine-free cigarettes, and the longest time to lapse for nicotine lozenge because the cigarette condition groups will have experienced stronger attentional bias toward cues, and more dependence prior to the quit date and greater withdrawal after the quit date.

Tobacco Dependence

National Institute on Drug Abuse (NIDA)66 participantsStarted Mar 2005

Minneapolis, Minnesota, United States

COMPLETEDPhase 1< 1 mile

Acute Withdrawal From Smoked Cocaine - 9

NCT00000292

The purpose of this study is to develop an experimental paradigm to examine acute withdrawal symptoms from cocaine.

National Institute on Drug Abuse (NIDA)Started Apr 1996

Minneapolis, Minnesota, United States

Comparisons of Nicotine-free Cigarettes, Extra Low Nicotine Cigarettes vs. Medicinal Nicotine

Acute Withdrawal From Smoked Cocaine - 9

Find Trials by Condition in Minneapolis

Role of Metabolites in Nicotine Dependence (1) - 1

Effects of Phenytoin on Cocaine Use in Humans - 2

Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10

Trial of NovoSeven® in Haemophilia - Joint Bleeds

Efficacy of NicVAX in Smokers Who Want to Quit Smoking

Heart and Hands Study II: A Retrospective Data Collection & Analysis Project

Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Use of Activated Recombinant FVII in Spinal Surgery

Randomized Trial of the Positive Action Program in Hawaii Schools

HIV and HCV Intervention In Drug Treatment Settings - 1

Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%

HIV/STD Safer Sex Skills Groups for Men in Drug Treatment Programs - 1

Job-Seekers Training for Patients With Drug Dependence - 1

Use of Activated Recombinant Human Factor VII in Cardiac Surgery

Motivational Interviewing to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse - 1

Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies